|
Insulin Lyspro recombinant
resources
|
|
|
|
|
|
DRUG INFO
Insulin Lyspro recombinant
Drug Name:
Insulin Lyspro recombinant
Indication: For treatment of diabetes (type I and II)
Pharmacology: Used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat.
Mechanism Of Action: Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.
Drug Category: Hypoglycemic Agents; insulins (68:20.08)
Brand Names/Synonyms: Humalog; Insulin Lispro; Humalog (Eli Lily); Insulin Lispro (Eli Lily)
Dosage Forms: LIQUID
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human Insulin
Chemical Formula: C257H387N65O76S6 >B chain
Half Life: 30 hours (mammalian reticulocytes, in vitro).
Drug Type: Approved Drug
# Accession No: BIOD00065
CAS Registry Number: 133107-64-9
|
|
|
|
|
|
Insulin Lyspro recombinant News
(When available)
Kris Freeman Collects Third National Title Jan 9, 2006
OUTDOORNEWSWIRE, Freeman, a diabetic who self-injects insulin from a Lilly Humalog pen six or eight times a day depending on elevation and other circumstances, said he battled ...
Alba Therapeutics Announces Upcoming Trials in Celiac Disease and ... Dec 23, 2005
PR Newswire (press release), ...discovery and development of several Lilly drugs, including Humulin(R), Humatrope(R), Evista(R), Xigris(R), and Forteo(R) and was co-inventor of Humalog(R). "Dr ...
Alba Therapeutics Announces Upcoming Trials in Celiac Disease and ... Dec 23, 2005
Yahoo! News (press release) ...in the discovery and development of several Lilly drugs, including Humulin®, Humatrope®, Evista®, Xigris®, and Forteo® and was co-inventor of Humalog®. ...
SciGen establishes China manufacturing facility Dec 14, 2005
In-PharmaTechnologist.com, Novo Nordisk, with 32 per cent (eg Novolin – $1.1 billion in 2004 – and Novolog), Eli Lilly, with 54 per cent (Humalog and Humulin, each grossing about $1 ...
|
|
|
